The Alzheimer’s Association is celebrating the FDA Advisory Council’s unanimous endorsement of donanemab, a promising new drug for early Alzheimer’s and mild cognitive impairment.
Julie Gray, director of development for the Alzheimer’s Association of West Texas, expressed excitement about the progress: “These are just tremendous steps forward, and we can’t wait for the FDA approval so that we have two officially approved drugs.”
Donanemab targets amyloid plaques, protein clumps in the brain associated with Alzheimer’s Disease. As per to the source theguardian
By reducing these plaques, the drug aims to slow cognitive decline, offering hope to millions of patients and their families.
“It’s such a hopeful time and really meaningful to those families,” Gray added. “Having more options available is always exciting news for our constituents.”
Related Articles:
- New Study Highlights High Fatality Rates in Texas Shrimping Industry
- North Texas Liquor Store Shoplifter Fails to Evade Arrest
- Top Dad Rock Bands in Texas, New Mexico, and Arizona
While the Advisory Council’s endorsement is not a final FDA approval, it marks a crucial step towards that goal.
Gray highlighted the impact of Alzheimer’s, noting, “There’s almost seven million Americans living with Alzheimer’s Disease, with 400,000 in Texas alone. This progress fills me with joy and hope that we’re moving closer to a cure.”
This development represents a significant stride in the fight against Alzheimer’s, bringing new hope to those affected by the disease.